Top Menu


Sculptra-poly-L-lactic-acid-logoSculptra is a synthetic injectable material known as poly-L-lactic acid (PLLA), a bio-compatible and biodegradable material that has been widely used for many years in dissolvable suture material and soft tissue implants [surgical products]. Sculptra is not made from human or animal sources and does not require a skin test. Sculptra provides a gradual and significant increase in fullness and volume by increasing your body’s own collagen production.

Sculptra is FDA-approved for the correction of nasolabial folds, contour deficiencies, and other facial wrinkles. Sculptra is also approved for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus. In this manner, Sculptra may be used to improve the general volume loss (fat and boney atrophy) associated with aging, with remarkable results. Sculptra is injected at different depths below the surface of the skin, in the area of fat loss, to restore volume and improve the appearance of facial contour irregularities. Sculptra can be used to replace lost volume in the cheeks, to enhance fullness in the temples, to define the angle of the jaw, and to treat nasolabial folds, marionette lines, perimental hollows, and the prejowl sulcus.

People with mild volume loss will require fewer treatments than those with more severe volume loss; most patients require two treatments spaced four to six weeks apart. Those individuals with more significant volume loss may need a third treatment, performed two to three months later. Touch-up treatments are recommended to maintain the desired effects. Sculptra treatments are a great way to provide a comprehensive approach to volume restoration of the entire face. The effects of Sculptra may last 2 years or longer. Poly-L-lactic acid (Sculptra™) has been safely used outside the United States since 1999 under the trade name New-Fill™. According to The American Society for Aesthetic Plastic Surgery, 79,313 Sculptra treatments were performed in the US in 2014.